Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Convertible Debt: 2022-2025

Historic Convertible Debt for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $198.3 million.

  • Gossamer Bio's Convertible Debt rose 0.49% to $198.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.3 million, marking a year-over-year increase of 0.49%. This contributed to the annual value of $197.5 million for FY2024, which is 0.47% up from last year.
  • As of Q3 2025, Gossamer Bio's Convertible Debt stood at $198.3 million, which was up 0.13% from $198.0 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Convertible Debt high stood at $198.3 million for Q3 2025, and its period low was $195.1 million during Q1 2022.
  • For the 3-year period, Gossamer Bio's Convertible Debt averaged around $197.1 million, with its median value being $197.1 million (2024).
  • Data for Gossamer Bio's Convertible Debt shows a peak YoY increased of 0.49% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Gossamer Bio's Convertible Debt stood at $195.7 million in 2022, then rose by 0.45% to $196.6 million in 2023, then climbed by 0.47% to $197.5 million in 2024, then climbed by 0.49% to $198.3 million in 2025.
  • Its Convertible Debt was $198.3 million in Q3 2025, compared to $198.0 million in Q2 2025 and $197.8 million in Q1 2025.